C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical pioneer in targeted protein degradation, will present at the Evercore ISI 3rd Annual HealthCONx on December 3, 2020, at 8:25 a.m. ET.
Investors can access a live webcast of the presentation on the company’s website, with a replay available for two weeks post-event. C4T focuses on therapeutics that selectively destroy disease-causing proteins, offering potential advantages over traditional treatments, particularly in cancer and neurodegenerative diseases.
Positive
- None.
Negative
- None.
News Market Reaction – CCCC
In the trading session that priced this news, CCCC gained 4.07%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.